Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 13/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.41 |
| ▸ | PDE4A | P27815 | 11/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | MDH1 | P40925 | 1/20 | 0.36 |
| ▸ | MDH2 | P40926 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18054821 | 0.82 | CA12 (0.47) | MAPTMDH1MDH2 | |
| SCHEMBL18033077 | 0.81 | MAPT (0.38) | MAPTMDH1MDH2 | |
| SCHEMBL18031267 | 0.81 | PDE4B (0.47) | PDE4DPDE4BPDE4APDE4CMAPT | |
| SCHEMBL18031239 | 0.81 | PDE4D (0.49) | PDE4DPDE4BPDE4APDE4CMAPT | |
| SCHEMBL1665370 | 0.81 | S1PR4 (0.47) | MAPT | |
| SCHEMBL26814603 | 0.81 | CYP1A2 (0.44) | MAPTMDH1MDH2 | |
| SCHEMBL18033365 | 0.80 | SMPD1 (0.50) | MAPT | |
| SCHEMBL25314479 | 0.79 | MRGPRX4 (0.47) | MAPT | |
| SCHEMBL20976380 | 0.79 | RAB9A (0.42) | MAPT | |
| SCHEMBL18031253 | 0.78 | MAPT (0.53) | PDE4DPDE4BPDE4APDE4CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358453-B2 | Antiviral compounds | ALIOS BIOPHARMA, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358453-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | PDE4D 1564/4885PDE4B 636/4885PDE4A 700/4885 |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | PDE4D 1564/4885PDE4B 636/4885PDE4A 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.